Mucoepidermoid Carcinoma (MUCC)

Overview

Mucoepidermoid Carcinoma is the most common salivary gland malignancy, sitting under SACA in OncoTree. It is graded (low, intermediate, high) and characterized molecularly by MAML2 fusions in a subset of cases. Advanced/recurrent MUCC may harbor HRAS mutations with therapeutic implications.

Cohorts in the corpus

  • hnc_mskcc_2016 — included as part of 20 “other salivary” carcinomas in 151 recurrent/metastatic head and neck tumors profiled by MSK-IMPACT 410-gene panel PMID:27442865.

Recurrent alterations

  • HRAS — G13V mutation identified in at least 1 recurrent/metastatic MUCC patient in the MSK-IMPACT cohort; treated on a farnesyl-transferase-inhibitor trial PMID:27442865.

Subtypes

  • Histologic grading (low/intermediate/high) is the primary clinical stratifier; high-grade MUCC behaves aggressively and has limited systemic therapy options.

Therapeutic landscape

  • Farnesyl-transferase inhibitors — explored for HRAS-mutant MUCC in the basket-trial context of the MSK-IMPACT cohort PMID:27442865.

Sources

  • PMID:27442865 — Morris et al. 2017 (JAMA Oncol). HRAS G13V mutation in recurrent/metastatic MUCC; basket trial enrollment on farnesyl-transferase inhibitor.

This page was processed by crosslinker on 2026-05-14.